PRELOAD PRELOAD PRELOAD PRELOAD PRELOAD

Content on this page requires a newer version of Adobe Flash Player.

Get Adobe Flash player

With five products on the market and a fully-integrated multinational organization in place, BioMarin is providing innovative therapeutics to patients with serious unmet medical needs.

LATEST NEWS

  • BioMarin's VIMIZIM(R) (elosulfase alfa) Approved in Brazil for Treatment of Morquio A Syndrome...  MORE >
  • FDA Grants BioMarin Orphan Drug Designation for NAGLU Fusion Protein, BMN 250, for the Treatment of MPS IIIB (Sanfilippo Syndrome Type B)...  MORE >
  • BioMarin to Highlight Breadth of Innovative Development Pipeline at Analyst and Investor Day on December 10th in New York...  MORE >